|
KMID : 4412620190250010012
|
|
Clinical Hypertension
2019 Volume.25 No. 1 p.12 ~ p.12
|
|
|
Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
|
|
Zhu Xiaolei
Wu Shenhong
|
|
|
Abstract
|
|
|
Background: Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined. We performed a systematic review and meta-analysis of randomized clinical trials to determine its overall risk.
Methods: Databases including Pubmed (up to July 2018) and Google scholar (up to July 2018) were searched to identify relevant studies. Eligible studies were prospective randomized clinical trials with prostate cancer treated with abiraterone and prednisone. The incidence and relative risk (RR) of hypertension was calculated using random-effects or fixed-effects model depending on the heterogeneity of included studies.
Results: A total of five studies including 5445 patients were selected for analysis. Among patients receiving abiraterone, the overall incidences of all grade and high grade (grade 3 and 4) were 21.9% (95% CI: 13.6?33.2%) and 10.2% % (95% CI: 6.9?11.6%). Abiraterone was associated with a significantly increased risk of hypertension of all grade with a relative risk of 1.80 (95% CI: 1.47?2.19%, p?
Conclusion: There is a significant increase of developing hypertension in prostate cancer patients treated with abiraterone. Appropriate monitoring and management is strongly recommended to reduce the risk of cardiovascular events and treatment interruptions.
|
|
|
KEYWORD
|
|
|
Abiraterone, Prostate cancer, Hypertension, Adverse event, Risk
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|